by Mark Mitchell, Co-Founder & General Partner at Weave VC
Welcome to Frostbite. Join us as we uncover valuable insights from Canada’s top technology investors, leaders, and innovators. Hosted by Weave VC Co-founder & General Partner, Mark Mitchell. Check out our blog: https://medium.com/@weave.vc Follow us on LinkedIn: https://www.linkedin.com/company/7710458 Connect with us on X: https://twitter.com/WeaveVC
Language
🇺🇲
Publishing Since
6/2/2021
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
September 18, 2023
<p>We had a chance to sit down with our friend Chris Robson for a deep dive into startup fundraising. Chris is the CEO & Co-founder at Edmonton based Wyvern, a space data company enabling next-generation earth observation using hyper-spectral cameras. </p> <p><br></p> <p>If you're an entrepreneur thinking about that first raise, be sure to listen in as Chris shares some of his learnings after successfully raising $17.M in capital from some of North America's top seed investors including MaC Venture Capital, Uncork Capital, Y-Combinator, and Soma Capital. </p> <p><br></p> <p>We were fortunate enough to participate in Wyvern's early rounds of financing through our angel syndicate Red Thread Ventures and our venture capital firm Weave VC and have been amazed at their progress over the past few years!</p> <p><br></p> <p>For more information on Wyvern and their offerings, please visit them online at https://wyvern.space/</p>
May 23, 2023
<p>Today’s guest is <a href="https://www.linkedin.com/in/madsdaugaard/" target="_blank" rel="noopener noreferer">Dr. Mads Daugaard</a>. Mads is the Co-founder, President and Chief Scientific Officer at Canadian cancer therapeutics company, <a href="https://www.rakovinatherapeutics.com/" target="_blank" rel="noopener noreferer">Rakovina Therapeutics</a>, a Red Thread Ventures portfolio company. This is his third time on our podcast and in today’s session we focused on Rakovina’s 2022 progress, their partnership with the St.Baldrick's foundation, distinctions between first generation/next generation therapies, and their push to IND filing and human clinical trials. We hope you enjoy today’s discussion with Dr. Mads Daugaard!</p> <p><br></p> <p>Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information can be found at <a href="http://www.rakovinatherapeutics.com">www.rakovinatherapeutics.com</a>, on <a href="https://www.linkedin.com/company/rakovina-therapeutics-inc/?viewAsMember=true" target="_blank" rel="noopener noreferer">LinkedIn</a>, and on Twitter @rakovina_rkv. </p> <p><br></p> <p>Red Thread Ventures has featured Rakovina in multiple blog posts, head over to <a href="http://www.redthread.ventures">www.redthread.ventures/blog</a> to learn more.</p>
April 29, 2022
<p>Dr. Mads Daugaard is the Co-founder, President and Chief Scientific Officer at biotech company, Rakovina Therapeutics. Founded in 2020, Rakovina is striving to revolutionize cancer treatment and extend the lives of cancer patients. Not yet in human clinical trials, they are developing medicines that selectively target and kill cancer cells using leading-edge science that we’ll discuss with Mads in this episode. The therapeutics company has 3 research programs, Kt-2000, 3000 and 4000, all of which are in the preclinical stage of drug development. Rakovina is currently being traded on the TSX Venture Exchange under the symbol RKV.</p> <p><br></p> <p>On April 8th in New Orleans, Mads is attending the American Association for Cancer Research or AACR annual meeting, which is the largest cancer research conference. Following that he is sharing an abstract highlighting Rakovina’s KT-3000 series at AACR’s special conference on Sarcoma cancer in Montreal. The episode highlights why it is so important for Rakovina and other preclinical biotech companies to attend conferences like these. </p> <p><br></p> <p>To learn more about Rakovina's presentation at the AARC conference, you can view their press release <a href="https://financialpost.com/globe-newswire/rakovina-therapeutics-presents-preclinical-data-supporting-potential-broad-anticancer-activity-of-kt-4000-series-at-the-american-association-of-cancer-research-aacr-annual-general-meeting">here</a>.</p> <p>To continue your dive into biotech investing, check out this blog series featuring Rakovina: <a href="https://www.redthread.ventures/blog/debunking-myths&risks-in-early-stage-biotech-investing-reverse-takeovers">Myths and Risks in Biotech Investing</a></p> <p><br></p> <p><strong>Rakovina Therapeutics</strong></p> <p><a href="https://www.rakovinatherapeutics.com/">Website </a></p> <p><a href="https://www.linkedin.com/company/rakovina-therapeutics-inc/about/">LinkedIn </a></p> <p><a href="https://twitter.com/rakovina_rkv">Twitter</a></p> <p><br></p> <p><strong>Red Thread Ventures </strong></p> <p><a href="https://www.redthread.ventures/">Website</a></p> <p><a href="https://www.linkedin.com/company/red-thread-ventures/">LinkedIn </a></p> <p><a href="https://www.youtube.com/channel/UCajikOJkZgV9t--ZSZRtl1Q">Youtube</a></p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
Welcome to Frostbite. Join us as we uncover valuable insights from Canada’s top technology investors, leaders, and innovators. Hosted by Weave VC Co-founder & General Partner, Mark Mitchell.
Check out our blog: https://medium.com/@weave.vc
Follow us on LinkedIn: https://www.linkedin.com/company/7710458
Connect with us on X: https://twitter.com/WeaveVC
This podcast updates daily.
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Yes, this podcast regularly features guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.